Marc Montserrat Appointed CEO of DNA Script
DNA Script, a prominent figure in enzymatic DNA synthesis, proudly announces the appointment of Marc Montserrat as its new Chief Executive Officer. This major leadership transition also sees founding CEO Thomas Ybert, PhD, moving into the role of Chief Scientific Officer, where he will continue to guide the company’s innovative research and development initiatives.
Marc Montserrat's Expertise and Vision
Bringing over twenty years of leadership experience within the biotech and life sciences sectors, Mr. Montserrat is well-equipped to drive DNA Script towards new heights. Before joining the company, he was a co-founder of Splice Bio, a leading genetic medicine enterprise, where he honed his skills in the biotech arena. His previous role at Ariosa Diagnostics enabled him to play a significant part in the expansion of the prenatal testing industry. Additionally, he has gained valuable insights at other innovative startups, including Omniome and Deepcell, where he made significant contributions to advancing sequencing technology and AI developments in biology.
Remarks from CEO Marc Montserrat
In his first statements as CEO, Mr. Montserrat conveyed his enthusiasm regarding his new position. "I am incredibly honored to join DNA Script at such a pivotal time," he stated. He acknowledged the revolutionary nature of the company’s achievements in DNA synthesis and expressed eagerness to collaborate with Thomas and the remarkable team to scale operations further and accelerate product development and commercialization.
Old and New Leadership Synergy
Mr. Montserrat reflected on the critical advancements that DNA Script has achieved during Dr. Ybert's tenure. He highlighted how the company has commercialized a disruptive enzymatic DNA synthesis technology, elevating it to unprecedented levels of performance. This innovation grants researchers access to new synthetic DNA products that were once beyond reach, thus opening various opportunities across the life sciences landscape, particularly in the biotech and pharmaceutical sectors. Applications include vaccine development, gene editing, cell therapies, and protein engineering.
Moving Ahead with Scientific Innovation
Dr. Ybert’s appointment to Chief Scientific Officer further solidifies DNA Script's commitment to groundbreaking scientific discovery and innovation. In his new role, he will steer the research efforts that form the foundation of the proprietary enzymatic DNA synthesis platform.
Celebrating Milestones and Future Aspirations
Expressing optimism about the future, Dr. Ybert emphasized the company's achievements since its inception, which include raising over €265 million in equity financing and filing more than 150 patent applications. The company has also successfully recorded over €20 million in revenue through the SYNTAX product line. With Marc's leadership and expertise, DNA Script is now ideally positioned to expedite its commercial success while continuing to innovate.
About DNA Script
DNA Script is at the forefront of life sciences technology, developing innovative methods to design and manufacture nucleic acids efficiently. The company pioneered an alternative to traditional chemical DNA synthesis with its enzymatic DNA synthesis technology, making it accessible via the revolutionary SYNTAX System. By empowering labs with this benchtop instrument, DNA Script transforms life sciences research, granting researchers greater control and independence in their work.
Frequently Asked Questions
Who has been appointed as the new CEO of DNA Script?
Marc Montserrat has been appointed as the new CEO of DNA Script.
What role does Thomas Ybert play at DNA Script after his transition?
Thomas Ybert has transitioned to the role of Chief Scientific Officer, focusing on the company’s research initiatives.
What is DNA Script known for?
DNA Script is recognized for its pioneering work in enzymatic DNA synthesis technology.
How does the SYNTAX System benefit researchers?
The SYNTAX System allows researchers to have more control and autonomy in designing and manufacturing nucleic acids.
What industry applications does DNA Script’s technology support?
DNA Script's technology supports various applications, including vaccine development, gene editing, and protein engineering.
